Benedikt Westphalen: CUPISCO is out in ESMO Open

Benedikt Westphalen, Medical Lead of Precision Oncology at the Cancer Center Munich, shared on LinkedIn:

“At ESMO2023 (European Society for Medical Oncology), the first results of the CUPISCO trial (NCT03498521) were presented by Linda Mileshkin.

Today, our open access research paper on the baseline mutational profile of 464 patients with unfavourable cancer of unknown primary enrolled into CUPISCO is out in ESMO Open.

In a preliminary molecular analysis, approximately one-third of CUP (Cancer of Unknown Primary) patients exhibited genomic alterations amenable to targeted therapies including but not limited to PIK3CA, FGFR2, ERBB2, and EGFR mutations.

Furthermore, we applied hierarchical clustering and found 10 distincts clusters based on specific co-occurrences of genomic alterations. This clustering did not not only reflected the genomic diversity of patients with CUP but also mirrored co-mutational patterns seen in known primary tumors, suggesting a shared oncogenic etiology.

I’m very grateful to the whole CUPISCO team for allowing me to be part of this: Alwin Krämer, Joel Federer-Gsponer, Chantal Pauli, Armen Karapetyan, Nasséra Chalabi, Gonzalo Durán Pacheco, Andreas Beringer, Tilmann Bochtler, Natalie Cook, Elen K. Höglander, Dexter X. Jin, Ferran Rosa, Holger Moch, Jeff Ross, Ethan Sokol, Richard Tothill and Marlene Thomas.”

For the article click here.
Source: Benedikt Westphalen/LinkedIn